Fusion Historical Income Statement
| FUSN Stock | USD 21.55 0.03 0.14% |
Historical analysis of Fusion Pharmaceuticals income statement accounts such as Depreciation And Amortization of 1.5 M or Interest Expense of 5.4 M can show how well Fusion Pharmaceuticals performed in making a profits. Evaluating Fusion Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Fusion Pharmaceuticals's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Fusion Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Fusion Pharmaceuticals is a good buy for the upcoming year.
Fusion |
About Fusion Income Statement Analysis
Fusion Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Fusion Pharmaceuticals shareholders. The income statement also shows Fusion investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Fusion Pharmaceuticals Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Fusion Pharmaceuticals. It is also known as Fusion Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Fusion Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Fusion Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fusion Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. To learn how to invest in Fusion Stock, please use our How to Invest in Fusion Pharmaceuticals guide.At this time, Fusion Pharmaceuticals' Total Other Income Expense Net is very stable compared to the past year. As of the 5th of June 2024, Income Tax Expense is likely to grow to about 826.4 K, though Tax Provision is likely to grow to (806.5 K).
| 2021 | 2022 | 2023 | 2024 (projected) | Reconciled Depreciation | 634K | 909K | 1.2M | 1.3M | Total Operating Expenses | 83.5M | 89.5M | 100.0M | 54.3M |
Fusion Pharmaceuticals income statement Correlations
Click cells to compare fundamentals
Fusion Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Fusion Pharmaceuticals income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Tax Provision | 251K | 2.6M | (118K) | (1.8M) | (849K) | (806.6K) | |
| Net Interest Income | 576K | 327K | 381K | 360K | 3.5M | 3.7M | |
| Depreciation And Amortization | 466K | 6.9M | 634K | 386K | 1.3M | 1.5M | |
| Interest Expense | 2.1M | 327K | 850K | 1.8M | 5.2M | 5.4M | |
| Selling General Administrative | 7.6M | 20.7M | 27.1M | 30.6M | 31.2M | 19.2M | |
| Other Operating Expenses | 18.0M | 37.9M | 83.5M | 89.5M | 101.3M | 54.5M | |
| Operating Income | (18.2M) | (37.9M) | (82.0M) | (88.0M) | (99.2M) | (94.3M) | |
| Net Income From Continuing Ops | (16.2M) | (78.3M) | (81.0M) | (88.0M) | (91.3M) | (86.8M) | |
| Ebit | (18.2M) | (37.9M) | (82.0M) | (88.0M) | (99.2M) | (94.3M) | |
| Research Development | 10.6M | 17.2M | 56.4M | 58.9M | 68.8M | 35.2M | |
| Ebitda | (17.8M) | (31.1M) | (81.4M) | (87.6M) | (97.9M) | (93.0M) | |
| Total Operating Expenses | 18.0M | 37.9M | 83.5M | 89.5M | 100.0M | 54.3M | |
| Reconciled Depreciation | 290K | 482K | 634K | 909K | 1.2M | 1.3M | |
| Income Before Tax | (15.9M) | (75.7M) | (81.2M) | (89.4M) | (94.1M) | (89.4M) | |
| Total Other Income Expense Net | 2.3M | (37.8M) | 850K | (1.4M) | 5.1M | 5.4M | |
| Net Income Applicable To Common Shares | (16.2M) | (79.7M) | (81.0M) | (87.6M) | (78.9M) | (74.9M) | |
| Net Income | (16.2M) | (78.3M) | (81.0M) | (87.6M) | (94.9M) | (90.2M) | |
| Income Tax Expense | 251K | 2.6M | (118K) | (1.8M) | 787K | 826.4K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectAdditional Information and Resources on Investing in Fusion Stock
When determining whether Fusion Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Fusion Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Fusion Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Fusion Pharmaceuticals Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fusion Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. To learn how to invest in Fusion Stock, please use our How to Invest in Fusion Pharmaceuticals guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fusion Pharmaceuticals. If investors know Fusion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fusion Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.40) | Revenue Per Share 0.028 | Quarterly Revenue Growth (1.00) | Return On Assets (0.23) | Return On Equity (0.47) |
The market value of Fusion Pharmaceuticals is measured differently than its book value, which is the value of Fusion that is recorded on the company's balance sheet. Investors also form their own opinion of Fusion Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Fusion Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fusion Pharmaceuticals' market value can be influenced by many factors that don't directly affect Fusion Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fusion Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fusion Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fusion Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.